Company / R&D Expense
PROKIDNEY CORP. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$127.7M
FY2024
5-year range
$21.0M / $127.7M
FY2020-FY2024
Trend
+19.6%
vs FY2023
Sector context
#116 of 210
Health Care
What the data says
At $128M, PROKIDNEY CORP.'s r&d expense ranks #116 of 210 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $21M in FY2020 to $128M in FY2024.
Based on SEC 10-K filings.
$128M in FY2024 with a 3-year CAGR of +40.3%.
Improved from $82M to $128M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +40.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#116 of 210 in Health CareTop 55% of 210This company $127.7M Sector average $644.1M
▼
-80.2% below sector average
Key checks
Key Insights
- PROKIDNEY CORP.'s r&d expense has grown for 4 consecutive years.
- 3-year CAGR of +40.3%, indicating consistent growth.
- In FY2024, r&d expense increased 19.6% year-over-year.
- Ranks #116 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.00 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $127.7M | +19.6% |
| FY2023 | $106.7M | +30.0% |
| FY2022 | $82.1M | +77.4% |
| FY2021 | $46.3M | +119.8% |
| FY2020 | $21.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026